High-Density Lipoproteins and Cardiovascular Disease: The Good, the Bad, and the Future II
- PMID: 35327422
- PMCID: PMC8945336
- DOI: 10.3390/biomedicines10030620
High-Density Lipoproteins and Cardiovascular Disease: The Good, the Bad, and the Future II
Abstract
The notion that high-density lipoproteins (HDL) are atheroprotective is supported by different lines of evidence [...].
Conflict of interest statement
The authors declare no conflict of interest. The funders had no role in the development of this Special Issue, in the writing of this manuscript, or in the decision to publish it.
References
-
- Kanbay M., Solak Y., Unal H.U., Kurt Y.G., Gok M., Cetinkaya H., Karaman M., Oguz Y., Eyileten T., Vural A., et al. Monocyte count/HDL cholesterol ratio and cardiovascular events in patients with chronic kidney disease. Int. Urol. Nephrol. 2014;46:1619–1625. doi: 10.1007/s11255-014-0730-1. - DOI - PubMed
-
- Coimbra S., Reis F., Valente M.J., Rocha S., Catarino C., Rocha-Pereira P., Sameiro-Faria M., Bronze-da-Rocha E., Belo L., Santos-Silva A. Subpopulations of High-Density Lipoprotein: Friends or Foes in Cardiovascular Disease Risk in Chronic Kidney Disease? Biomedicines. 2021;9:554. doi: 10.3390/biomedicines9050554. - DOI - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Research Materials
